Wall Street brokerages forecast that Celldex Therapeutics, Inc. (NASDAQ:CLDX) will report ($0.12) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Celldex Therapeutics’ earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.17). Celldex Therapeutics reported earnings of ($0.14) per share during the same quarter last year, which would indicate a positive year over year growth rate of 14.3%. The business is expected to announce its next quarterly earnings report on Tuesday, November 6th.
On average, analysts expect that Celldex Therapeutics will report full-year earnings of ($1.15) per share for the current year, with EPS estimates ranging from ($1.26) to ($1.06). For the next financial year, analysts expect that the company will report earnings of ($0.53) per share, with EPS estimates ranging from ($0.72) to ($0.26). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Celldex Therapeutics.
Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.03. Celldex Therapeutics had a negative return on equity of 47.40% and a negative net margin of 1,159.26%. The firm had revenue of $2.76 million during the quarter, compared to analyst estimates of $2.70 million.
Several research firms have recently weighed in on CLDX. HC Wainwright set a $2.00 price objective on Celldex Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 9th. Zacks Investment Research lowered Celldex Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 3rd. Cowen reissued a “hold” rating on shares of Celldex Therapeutics in a research report on Thursday, August 9th. Finally, Jefferies Financial Group restated a “hold” rating on shares of Celldex Therapeutics in a research note on Friday, August 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $3.75.
Shares of CLDX stock traded down $0.01 during mid-day trading on Friday, hitting $0.41. The company’s stock had a trading volume of 1,929,000 shares, compared to its average volume of 2,235,763. Celldex Therapeutics has a 52 week low of $0.40 and a 52 week high of $3.09. The firm has a market cap of $71.80 million, a PE ratio of -0.51 and a beta of 2.29.
Several institutional investors and hedge funds have recently modified their holdings of CLDX. BlackRock Inc. grew its stake in shares of Celldex Therapeutics by 1.7% in the 1st quarter. BlackRock Inc. now owns 10,097,481 shares of the biopharmaceutical company’s stock valued at $23,527,000 after buying an additional 166,780 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Celldex Therapeutics by 3,392.4% in the 1st quarter. JPMorgan Chase & Co. now owns 991,184 shares of the biopharmaceutical company’s stock valued at $2,309,000 after buying an additional 962,803 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Celldex Therapeutics by 74.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 4,167,585 shares of the biopharmaceutical company’s stock valued at $9,710,000 after buying an additional 1,783,765 shares during the period. Acadian Asset Management LLC grew its stake in shares of Celldex Therapeutics by 378.4% in the 2nd quarter. Acadian Asset Management LLC now owns 1,157,880 shares of the biopharmaceutical company’s stock valued at $583,000 after buying an additional 915,863 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Celldex Therapeutics by 27.7% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 900,185 shares of the biopharmaceutical company’s stock valued at $453,000 after buying an additional 195,147 shares during the period. Institutional investors own 33.48% of the company’s stock.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.
Featured Article: What are the benefits of buying treasury bonds?
Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.